Protagonist Therapeutics, Inc.
PTGX
$96.75
$4.394.75%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 57.83% | -15.04% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 57.83% | -15.04% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 57.83% | -15.04% | |||
| SG&A Expenses | 2.73% | 5.49% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.02% | 7.45% | |||
| Operating Income | -8.47% | -10.42% | |||
| Income Before Tax | -11.13% | -13.70% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -12.82% | -13.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -12.82% | -13.14% | |||
| EBIT | -8.47% | -10.42% | |||
| EBITDA | -8.51% | -10.36% | |||
| EPS Basic | -12.37% | -12.68% | |||
| Normalized Basic EPS | -10.71% | -13.22% | |||
| EPS Diluted | -12.61% | -12.73% | |||
| Normalized Diluted EPS | -10.71% | -13.22% | |||
| Average Basic Shares Outstanding | 0.41% | 0.41% | |||
| Average Diluted Shares Outstanding | 0.41% | 0.41% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||